What caused the FINRA short volume ratio for CRDF to decrease from 58.19% on July 30, 2025, to 34.79% on August 6, 2025?

The significant decrease in the FINRA short volume ratio for Cardiff Oncology, Inc. (CRDF) from 58.19% on July 30, 2025, to 34.79% on August 6, 2025, was likely influenced by a positive analyst rating during that period.

On July 8, 2025, Ladenburg Thalmann initiated coverage of Cardiff Oncology (NasdaqCM:CRDF) with a "Buy" recommendation.1 Such a positive initiation from an investment firm can signal increased confidence in a company's prospects, potentially prompting short sellers to cover their positions to mitigate risk, thereby reducing the short volume ratio.

While a subsequent price target decrease by George Maybach on July 17, 2025, revised the average one-year price target to $12, this was still substantially higher than the stock's actual price of $2.45 per share as of August 6, 2025.1 Additionally, HC Wainwright & Co. maintained its "Buy" rating for CRDF on August 6, 2025, reinforcing a generally positive analyst sentiment around the time of the short volume ratio decline.1

For more detailed information on CRDF's analyst ratings and news, you can visit Fintel's CRDF page.